ID   HL-60
AC   CVCL_0002
SY   HL 60; HL.60; HL60; Human Leukemia-60
DR   BTO; BTO:0000738
DR   CLO; CLO_0003775
DR   CLO; CLO_0050972
DR   EFO; EFO_0002793
DR   MCCL; MCC:0000195
DR   CLDB; cl1682
DR   CLDB; cl1684
DR   CLDB; cl1685
DR   CLDB; cl1686
DR   CLDB; cl1687
DR   CLDB; cl1688
DR   CLDB; cl1689
DR   CLDB; cl1690
DR   CLDB; cl1691
DR   CLDB; cl1693
DR   Abcam; ab282204
DR   AddexBio; C0003023/4977
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CCL-240
DR   BCRC; 60027
DR   BCRJ; 0104
DR   BioGRID_ORCS_Cell_line; 42
DR   BioSample; SAMN01821559
DR   BioSample; SAMN01821682
DR   BioSample; SAMN03472768
DR   BioSample; SAMN03473174
DR   BioSample; SAMN10988245
DR   cancercelllines; CVCL_0002
DR   CCRID; 1101HUM-PUMC000037
DR   CCRID; 1102HUM-NIFDC00098
DR   CCRID; 3101HUMTCHu23
DR   CCRID; 4201HUM-CCTCC00028
DR   CCTCC; GDC0027
DR   CCTCC; GDC0028
DR   Cell_Model_Passport; SIDM00829
DR   ChEMBL-Cells; CHEMBL3307654
DR   ChEMBL-Targets; CHEMBL383
DR   CLS; 300209
DR   Cosmic; 716179
DR   Cosmic; 716190
DR   Cosmic; 724817
DR   Cosmic; 787433
DR   Cosmic; 798224
DR   Cosmic; 798665
DR   Cosmic; 808506
DR   Cosmic; 821043
DR   Cosmic; 850380
DR   Cosmic; 851996
DR   Cosmic; 875866
DR   Cosmic; 905938
DR   Cosmic; 919116
DR   Cosmic; 922161
DR   Cosmic; 922683
DR   Cosmic; 924049
DR   Cosmic; 932769
DR   Cosmic; 947366
DR   Cosmic; 949099
DR   Cosmic; 975252
DR   Cosmic; 981578
DR   Cosmic; 991557
DR   Cosmic; 994170
DR   Cosmic; 999724
DR   Cosmic; 1012068
DR   Cosmic; 1019836
DR   Cosmic; 1037661
DR   Cosmic; 1070693
DR   Cosmic; 1078724
DR   Cosmic; 1089519
DR   Cosmic; 1092602
DR   Cosmic; 1107177
DR   Cosmic; 1127250
DR   Cosmic; 1130234
DR   Cosmic; 1168468
DR   Cosmic; 1176580
DR   Cosmic; 1181599
DR   Cosmic; 1191695
DR   Cosmic; 1192826
DR   Cosmic; 1226863
DR   Cosmic; 1281315
DR   Cosmic; 1305337
DR   Cosmic; 1308224
DR   Cosmic; 1319549
DR   Cosmic; 1451845
DR   Cosmic; 1465966
DR   Cosmic; 1523825
DR   Cosmic; 1524830
DR   Cosmic; 1582390
DR   Cosmic; 1601062
DR   Cosmic; 1604861
DR   Cosmic; 1998444
DR   Cosmic; 2036678
DR   Cosmic; 2089652
DR   Cosmic; 2131539
DR   Cosmic; 2301565
DR   Cosmic; 2306208
DR   Cosmic; 2651387
DR   Cosmic-CLP; 905938
DR   DepMap; ACH-000002
DR   DSMZ; ACC-3
DR   DSMZCellDive; ACC-3
DR   ECACC; 98070106
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS069ENC
DR   ENCODE; ENCBS070ENC
DR   ENCODE; ENCBS215JQI
DR   ENCODE; ENCBS308XSW
DR   ENCODE; ENCBS373UEY
DR   ENCODE; ENCBS482VCU
DR   ENCODE; ENCBS698WLF
DR   ENCODE; ENCBS869DKF
DR   ENCODE; ENCBS880XNW
DR   GDSC; 905938
DR   GEO; GSM50194
DR   GEO; GSM50258
DR   GEO; GSM213809
DR   GEO; GSM236782
DR   GEO; GSM236818
DR   GEO; GSM472908
DR   GEO; GSM472942
DR   GEO; GSM482507
DR   GEO; GSM545496
DR   GEO; GSM545497
DR   GEO; GSM743458
DR   GEO; GSM749688
DR   GEO; GSM749775
DR   GEO; GSM750812
DR   GEO; GSM799346
DR   GEO; GSM799409
DR   GEO; GSM838428
DR   GEO; GSM838429
DR   GEO; GSM838430
DR   GEO; GSM838431
DR   GEO; GSM887083
DR   GEO; GSM888153
DR   GEO; GSM945222
DR   GEO; GSM945255
DR   GEO; GSM1153417
DR   GEO; GSM1181331
DR   GEO; GSM1181348
DR   GEO; GSM1374535
DR   GEO; GSM1374536
DR   GEO; GSM1446736
DR   GEO; GSM1669883
DR   GEO; GSM2716740
DR   GEO; GSM2716741
DR   GEO; GSM2716742
DR   GEO; GSM2716743
DR   IARC_TP53; 21372
DR   IARC_TP53; 21731
DR   ICLC; HTL95010
DR   IGRhCellID; HL60
DR   IZSLER; BS TCL 25
DR   JCRB; IFO50022
DR   JCRB; JCRB0085
DR   JCRB; NIHS0086
DR   KCB; KCB 2014051YJ
DR   KCLB; 10240
DR   LiGeA; CCLE_789
DR   LINCS_LDP; LCL-1054
DR   Lonza; 64
DR   MeSH; D018922
DR   NCBI_Iran; C217
DR   PharmacoDB; HL60_546_2019
DR   PRIDE; PRD000345
DR   PRIDE; PXD000589
DR   PRIDE; PXD006421
DR   PRIDE; PXD030304
DR   PRIDE; PXD032942
DR   Progenetix; CVCL_0002
DR   PubChem_Cell_line; CVCL_0002
DR   RCB; RCB0041
DR   RCB; RCB3683
DR   SKY/M-FISH/CGH; 5609
DR   TKG; TKG 0345
DR   TOKU-E; 1488
DR   Ubigene; YC-C058
DR   Wikidata; Q5630035
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   DOI=10.1159/000415060;
RX   PubMed=271272;
RX   PubMed=288488;
RX   PubMed=1368402;
RX   PubMed=1574572;
RX   PubMed=1970118;
RX   PubMed=2140233;
RX   PubMed=2545346;
RX   PubMed=2858093;
RX   PubMed=2985879;
RX   PubMed=3159941;
RX   PubMed=3311197;
RX   PubMed=3335022;
RX   PubMed=3422031;
RX   PubMed=3860286;
RX   PubMed=3874327;
RX   PubMed=6091813;
RX   PubMed=6255959;
RX   PubMed=6582512;
RX   PubMed=6945469;
RX   PubMed=6954533;
RX   PubMed=6996765;
RX   PubMed=7630190;
RX   PubMed=8316623;
RX   PubMed=8343448;
RX   PubMed=8558913;
RX   PubMed=8562479;
RX   PubMed=9434637;
RX   PubMed=9510473;
RX   PubMed=9557624;
RX   PubMed=9607592;
RX   PubMed=9737686;
RX   PubMed=9738977;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=11416159;
RX   PubMed=12068308;
RX   PubMed=12661003;
RX   PubMed=15843827;
RX   PubMed=16120335;
RX   PubMed=16408098;
RX   PubMed=17088437;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22032829;
RX   PubMed=22068913;
RX   PubMed=22347499;
RX   PubMed=22460905;
RX   PubMed=22944676;
RX   PubMed=23955599;
RX   PubMed=24368162;
RX   PubMed=24670534;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25894527;
RX   PubMed=25984343;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28109323;
RX   PubMed=28196595;
RX   PubMed=29491412;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30670178;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=33389257;
RX   PubMed=35839778;
WW   https://en.wikipedia.org/wiki/HL60
WW   https://www.phe-culturecollections.org.uk/media/154986/hl60-cell-line-profile.pdf
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=HL-60
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=32
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/HL-60_Stam_protocol.pdf
WW   https://www.proteinatlas.org/learn/cellines
WW   https://web.archive.org/web/20201109215324/www.infarktforschung.de/macrophages_cell_lines.html
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/h/cell-lines-detail-132.html
WW   https://tcpaportal.org/mclp/
CC   Group: Space-flown cell line (cellonaut).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: ENCODE project common cell types; tier 3.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: MYC genetic alteration cell panel (ATCC TCP-1035).
CC   Registration: National Institute of Standards and Technology, Standard Reference Materials; SRM 2392-I.
CC   Population: Caucasian.
CC   Biotechnology: Used a source of mitochondrial DNA for USA forensic testing.
CC   Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257).
CC   Doubling time: 16 hours (PubMed=8343448); 28 hours (PubMed=25984343); ~40 hours (DSMZ=ACC-3).
CC   HLA typing: A*01:01,24:15; B*57:01,57:01; C*06:02,06:02 (PubMed=26589293).
CC   HLA typing: B*57:01:01,57:01:01; C*06:02:01,06:02:01 (DSMZCellDive=ACC-3).
CC   Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; PubMed=12661003; Sanger).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=2858093).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (PubMed=17088437; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=12068308; PubMed=17088437; Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Cell surface proteome.
CC   Omics: CTCF ChIP-seq epigenome analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: CNV analysis.
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Mitochondrial genome sequenced.
CC   Omics: N-glycan profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.15%; Native American=0.42%; East Asian, North=0.4%; East Asian, South=0%; South Asian=0%; European, North=71.71%; European, South=26.32% (PubMed=30894373).
CC   Anecdotal: Established at the 60th attempt to culture human leukemia biopsies in Gallo's lab. All the preceding attempts having failed.
CC   Misspelling: IIL-60; Note=Occasionally.
CC   Discontinued: Abcam; ab282204; true.
CC   Discontinued: JCRB; NIHS0086; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): AddexBio; ATCC; CCRID; CLS; COG; Cosmic-CLP; DSMZ; ECACC; JCRB; KCLB; PubMed=11416159; PubMed=25877200; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 13,14
ST   D13S317: 8,11
ST   D16S539: 11
ST   D18S51: 14 (CLS)
ST   D18S51: 14,15 (CCRID; DSMZ; PubMed=11416159; PubMed=25877200)
ST   D19S433: 14
ST   D21S11: 29,30 (CCRID; COG; DSMZ; PubMed=25877200)
ST   D21S11: 30 (CLS; PubMed=11416159)
ST   D2S1338: 17
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 11,12
ST   D8S1179: 12 (DSMZ)
ST   D8S1179: 12,13 (CCRID; PubMed=11416159; PubMed=25877200)
ST   D8S1179: 13 (CLS)
ST   FGA: 22,24
ST   Penta D: 10,11 (DSMZ)
ST   Penta D: 10,12 (CLS; PubMed=25877200)
ST   Penta E: 13 (CLS)
ST   Penta E: 13,14 (DSMZ; PubMed=25877200)
ST   TH01: 7,8 (AddexBio; ATCC; CCRID; CLS; COG; Cosmic-CLP; DSMZ; KCLB; PubMed=11416159; PubMed=25877200; RCB; TKG)
ST   TH01: 8 (ECACC; JCRB)
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 48
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   DOI=10.1159/000415060;
RA   Morikawa S., Harada T., Katoh T.;
RT   "Heterogeneity of cellular origins in human malignant lymphoma cell
RT   line derived from histo-monocytic lineage cells.";
RL   (In) Cellular, molecular, genetic approaches to immunodiagnosis and immunotherapy. 8th International conference on labeled antibodies, Tokyo, November 1985; Kano K., Mori S., Sugisaki T., Torisu M. (eds.); pp.373-380; Karger; Basel (1988).
//
RX   PubMed=271272; DOI=10.1038/270347a0;
RA   Collins S.J., Gallo R.C., Gallagher R.E.;
RT   "Continuous growth and differentiation of human myeloid leukaemic
RT   cells in suspension culture.";
RL   Nature 270:347-349(1977).
//
RX   PubMed=288488; DOI=10.1182/blood.V54.3.713.713;
RA   Gallagher R.E., Collins S.J., Trujillo J.M., McCredie K., Ahearn M.J.,
RA   Tsai S., Metzgar R., Aulakh G., Ting R., Ruscetti F.W., Gallo R.C.;
RT   "Characterization of the continuous, differentiating myeloid cell line
RT   (HL-60) from a patient with acute promyelocytic leukemia.";
RL   Blood 54:713-733(1979).
//
RX   PubMed=1368402; DOI=10.1007/BF02540028;
RA   Schumpp B., Schlaeger E.-J.;
RT   "Growth study of lactate and ammonia double-resistant clones of HL-60
RT   cells.";
RL   Cytotechnology 8:39-44(1992).
//
RX   PubMed=1574572; DOI=10.2307/3578273;
RA   Dunphy E.J., Beckett M.A., Thompson L.H., Weichselbaum R.R.;
RT   "Expression of the polymorphic human DNA repair gene XRCC1 does not
RT   correlate with radiosensitivity in the cells of human head and neck
RT   tumor cell lines.";
RL   Radiat. Res. 130:166-170(1992).
//
RX   PubMed=1970118; DOI=10.1128/mcb.10.5.2154-2163.1990;
RA   Collins S.J., Robertson K.A., Mueller L.;
RT   "Retinoic acid-induced granulocytic differentiation of HL-60 myeloid
RT   leukemia cells is mediated directly through the retinoic acid receptor
RT   (RAR-alpha).";
RL   Mol. Cell. Biol. 10:2154-2163(1990).
//
RX   PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x;
RA   Nakano A., Harada T., Morikawa S., Kato Y.;
RT   "Expression of leukocyte common antigen (CD45) on various human
RT   leukemia/lymphoma cell lines.";
RL   Acta Pathol. Jpn. 40:107-115(1990).
//
RX   PubMed=2545346;
RA   Hindenburg A.A., Gervasoni J.E. Jr., Krishna S., Stewart V.J.,
RA   Rosado M., Lutzky J., Bhalla K.N., Baker M.A., Taub R.N.;
RT   "Intracellular distribution and pharmacokinetics of daunorubicin in
RT   anthracycline-sensitive and -resistant HL-60 cells.";
RL   Cancer Res. 49:4607-4614(1989).
//
RX   PubMed=2858093; DOI=10.1073/pnas.82.3.790;
RA   Wolf D., Rotter V.;
RT   "Major deletions in the gene encoding the p53 tumor antigen cause lack
RT   of p53 expression in HL-60 cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:790-794(1985).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3311197; DOI=10.1182/blood.V70.5.1233.1233;
RA   Collins S.J.;
RT   "The HL-60 promyelocytic leukemia cell line: proliferation,
RT   differentiation, and cellular oncogene expression.";
RL   Blood 70:1233-1244(1987).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3422031; DOI=10.1182/blood.V71.1.242.242;
RA   Dalton W.T. Jr., Ahearn M.J., McCredie K.B., Freireich E.J.,
RA   Stass S.A., Trujillo J.M.;
RT   "HL-60 cell line was derived from a patient with FAB-M2 and not
RT   FAB-M3.";
RL   Blood 71:242-247(1988).
//
RX   PubMed=3860286;
RA   Bhalla K.N., Hindenburg A.A., Taub R.N., Grant S.;
RT   "Isolation and characterization of an anthracycline-resistant human
RT   leukemic cell line.";
RL   Cancer Res. 45:3657-3662(1985).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=6091813; DOI=10.1182/blood.V64.5.1059.1059;
RA   Palumbo A., Minowada J., Erikson J., Croce C.M., Rovera G.;
RT   "Lineage infidelity of a human myelogenous leukemia cell line.";
RL   Blood 64:1059-1063(1984).
//
RX   PubMed=6255959; DOI=10.1016/0014-4827(81)90422-5;
RA   Olsson I., Olofsson T.;
RT   "Induction of differentiation in a human promyelocytic leukemic cell
RT   line (HL-60). Production of granule proteins.";
RL   Exp. Cell Res. 131:225-230(1981).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=6945469; DOI=10.1016/0145-2126(81)90018-7;
RA   Major P.P., Griffin J.D., Minden M.D., Kufe D.W.;
RT   "A blast subclone of the HL-60 human promyelocytic cell line.";
RL   Leuk. Res. 5:429-430(1981).
//
RX   PubMed=6954533; DOI=10.1073/pnas.79.7.2194;
RA   Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A.,
RA   Aaronson S.A., Wong-Staal F.;
RT   "Differential expression of the amv gene in human hematopoietic
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).
//
RX   PubMed=6996765; DOI=10.1182/blood.V56.3.344.344;
RA   Koeffler H.P., Golde D.W.;
RT   "Human myeloid leukemia cell lines: a review.";
RL   Blood 56:344-350(1980).
//
RX   PubMed=7630190;
RA   Zhou M.-X., Gu L.-B., James C.D., He J., Yeager A.M., Smith S.D.,
RA   Findley H.W.;
RT   "Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines
RT   established from children with acute lymphoblastic leukemia.";
RL   Leukemia 9:1159-1161(1995).
//
RX   PubMed=8316623; DOI=10.2307/3578190;
RA   Evans H.H., Ricanati M., Horng M.-F., Jiang Q.-Y., Mencl J.,
RA   Olive P.L.;
RT   "DNA double-strand break rejoining deficiency in TK6 and other human
RT   B-lymphoblast cell lines.";
RL   Radiat. Res. 134:307-315(1993).
//
RX   PubMed=8343448;
RA   Kajigaya Y., Sasaki H., Ikuta K., Matsuyama S., Hirabayashi Y.,
RA   Inoue T.;
RT   "Serum-free culture for leukemia cells.";
RL   Hum. Cell 6:49-56(1993).
//
RX   PubMed=8558913;
RA   Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M.,
RA   Imaizumi M., Endo M., Takano N., Konno T.;
RT   "Cell surface c-kit receptors in human leukemia cell lines and
RT   pediatric leukemia: selective preservation of c-kit expression on
RT   megakaryoblastic cell lines during adaptation to in vitro culture.";
RL   Leukemia 10:102-105(1996).
//
RX   PubMed=8562479;
RA   Banerjee D., Lenz H.-J., Schnieders B., Manno D.J., Ju J.-F.,
RA   Spears C.P., Hochhauser D., Danenberg K.D., Danenberg P.V.,
RA   Bertino J.R.;
RT   "Transfection of wild-type but not mutant p53 induces early monocytic
RT   differentiation in HL60 cells and increases their sensitivity to
RT   stress.";
RL   Cell Growth Differ. 6:1405-1413(1995).
//
RX   PubMed=9434637; DOI=10.1006/excr.1997.3813;
RA   Piepmeier E.H., Kalns J.E., McIntyre K.M., Lewis M.L.;
RT   "Prolonged weightlessness affects promyelocytic multidrug
RT   resistance.";
RL   Exp. Cell Res. 237:410-418(1997).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=9557624; DOI=10.1038/sj.leu.2400976;
RA   Mattii L., Barale R., Petrini M.;
RT   "Use of the comet test in the evaluation of multidrug resistance of
RT   human cell lines.";
RL   Leukemia 12:627-632(1998).
//
RX   PubMed=9607592;
RA   Ju J.-F., Banerjee D., Lenz H.-J., Danenberg K.D., Schmittgen T.C.,
RA   Spears C.P., Schonthal A.H., Manno D.J., Hochhauser D., Bertino J.R.,
RA   Danenberg P.V.;
RT   "Restoration of wild-type p53 activity in p53-null HL-60 cells confers
RT   multidrug sensitivity.";
RL   Clin. Cancer Res. 4:1315-1322(1998).
//
RX   PubMed=9737686; DOI=10.1038/sj.leu.2401112;
RA   Zhang W., Ohnishi K., Shigeno K., Fujisawa S., Naito K., Nakamura S.,
RA   Takeshita K., Takeshita A., Ohno R.;
RT   "The induction of apoptosis and cell cycle arrest by arsenic trioxide
RT   in lymphoid neoplasms.";
RL   Leukemia 12:1383-1391(1998).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=12661003; DOI=10.1002/gcc.10196;
RA   Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U.,
RA   Santibanez-Koref M.F., Schlag P.M., Scherneck S.;
RT   "Identification of microsatellite instability and mismatch repair gene
RT   mutations in breast cancer cell lines.";
RL   Genes Chromosomes Cancer 37:29-35(2003).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=16120335; DOI=10.1016/S1567-7249(03)00010-2;
RA   Levin B.C., Holland K.A., Hancock D.K., Coble M., Parsons T.J.,
RA   Kienker L.J., Williams D.W., Jones M., Richie K.L.;
RT   "Comparison of the complete mtDNA genome sequences of human cell
RT   lines-- HL-60 and GM10742A -- from individuals with pro-myelocytic
RT   leukemia and Leber hereditary optic neuropathy, respectively, and the
RT   inclusion of HL-60 in the NIST human mitochondrial DNA standard
RT   reference material -- SRM 2392-I.";
RL   Mitochondrion 2:387-400(2003).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433;
RA   Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K.M., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P.J.,
RA   Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22032829; DOI=10.1016/j.mrfmmm.2011.10.005;
RA   Luan Y., Kogi M., Rajaguru P., Ren J., Yamaguchi T., Suzuki K.,
RA   Suzuki T.;
RT   "Microarray analysis of responsible genes in increased growth rate in
RT   the subline of HL60 (HL60RG) cells.";
RL   Mutat. Res. 731:20-26(2012).
//
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
//
RX   PubMed=22347499; DOI=10.1371/journal.pone.0031628;
RA   Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.;
RT   "Mass homozygotes accumulation in the NCI-60 cancer cell lines as
RT   compared to HapMap trios, and relation to fragile site location.";
RL   PLoS ONE 7:E31628-E31628(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22944676; DOI=10.1515/hsz-2012-0195;
RA   Reinke S.O., Bayer M., Berger M., Hinderlich S., Blanchard V.;
RT   "The analysis of N-glycans of cell membrane proteins from human
RT   hematopoietic cell lines reveals distinctions in their pattern.";
RL   Biol. Chem. 393:731-747(2012).
//
RX   PubMed=23955599; DOI=10.1038/ng.2731;
RA   Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y.,
RA   Yoshida K.-i., Okuno Y., Bando M., Nakato R., Ishikawa S.,
RA   Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D.,
RA   Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K.,
RA   Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M.,
RA   Nakamaki T., Ishiyama K., Nolte F., Hofmann W.-K., Miyawaki S.,
RA   Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H.,
RA   Haferlach T., Shirahige K., Miyano S., Ogawa S.;
RT   "Recurrent mutations in multiple components of the cohesin complex in
RT   myeloid neoplasms.";
RL   Nat. Genet. 45:1232-1237(2013).
//
RX   PubMed=24368162; DOI=10.1016/j.exphem.2013.12.004;
RA   Sripayap P., Nagai T., Uesawa M., Kobayashi H., Tsukahara T.,
RA   Ohmine K., Muroi K., Ozawa K.;
RT   "Mechanisms of resistance to azacitidine in human leukemia cell
RT   lines.";
RL   Exp. Hematol. 42:294-306(2014).
//
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28109323; DOI=10.1186/s13045-017-0396-0;
RA   Masetti R., Bertuccio S.N., Astolfi A., Chiarini F., Lonetti A.,
RA   Indio V., De Luca M., Bandini J., Serravalle S., Franzoni M.,
RA   Pigazzi M., Martelli A.M., Basso G., Locatelli F., Pession A.;
RT   "Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion
RT   gene.";
RL   J. Hematol. Oncol. 10:26.1-26.5(2017).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29491412; DOI=10.1038/s41388-018-0150-2;
RA   Gerlach D., Tontsch-Grunt U., Baum A., Popow J., Scharn D.,
RA   Hofmann M.H., Engelhardt H., Kaya O., Beck J., Schweifer N.,
RA   Gerstberger T., Zuber J., Savarese F., Kraut N.;
RT   "The novel BET bromodomain inhibitor BI 894999 represses
RT   super-enhancer-associated transcription and synergizes with CDK9
RT   inhibition in AML.";
RL   Oncogene 37:2687-2701(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30670178; DOI=10.1016/j.jcf.2018.06.007;
RA   Jennings S., Ng H.P., Wang G.-S.;
RT   "Establishment of a DeltaF508-CF promyelocytic cell line for cystic
RT   fibrosis research and drug screening.";
RL   J. Cyst. Fibros. 18:44-53(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=33389257; DOI=10.1007/s10096-020-04106-0;
RA   Wurtz N., Penant G., Jardot P., Duclos N., La Scola B.;
RT   "Culture of SARS-CoV-2 in a panel of laboratory cell lines,
RT   permissivity, and differences in growth profile.";
RL   Eur. J. Clin. Microbiol. Infect. Dis. 40:477-484(2021).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//